OncoTherapy Science reports FY2026 net loss of Y910m

4 articles · Updated · MarketWatch · May 8

For the year ended 31 March, revenue rose to Y808 million from Y750 million, while the net loss widened from Y815 million.
Operating loss increased to Y810 million from Y797 million and pretax loss to Y845 million from Y815 million under Japanese accounting standards.
Per-share loss was Y2.77 versus Y3.12 a year earlier, despite higher revenue, indicating continued pressure on profitability.

In a booming global market, will Japan's unique pricing and accounting rules help or hinder this biotech innovator?

Is the company's unique HIG2 cancer target promising enough to justify its mounting financial losses?

As losses widen despite growing revenue, can its pipeline survive the harsh biotech funding climate?